Clinically Significant Interaction Between Diphenhydramine and Risperidone

Mechanism of Interaction and Clinical Consequences

• The combination of diphenhydramine and risperidone can cause additive sedative effects, particularly in vulnerable populations, due to CNS depression and sedation caused by both drugs 1, 2
• Diphenhydramine has significant anticholinergic properties that can worsen antipsychotic-induced anticholinergic effects, increasing the risk of delirium 1, 2
• Risperidone commonly causes extrapyramidal symptoms (EPS) and dystonic reactions, which can be paradoxically increased by chronic co-administration of diphenhydramine due to elevated risperidone levels 1
• Enhanced sedation and cognitive impairment are likely with this combination, particularly in elderly patients or those with cognitive impairment 2, 3
• The American Academy of Pediatrics recommends monitoring for sedation, hypotension, tachycardia, and anticholinergic effects when using the lowest effective doses of both agents 1
• The National Comprehensive Cancer Network recommends limiting the duration of concurrent use to minimize cumulative anticholinergic and sedative burden 3

Clinical Recommendations

• The American Academy of Pediatrics recommends using the lowest effective doses of both agents and monitoring closely for sedation, hypotension, tachycardia, and anticholinergic effects when combination is necessary 1
• Consider baseline and follow-up ECG in patients with cardiac risk factors given QTc prolongation risk, as recommended by the American Heart Association 3
• Limit duration of concurrent use to minimize cumulative anticholinergic and sedative burden, as recommended by the National Comprehensive Cancer Network 3

Diphenhydramine's Inhibition of CYP2D6 and Clinical Implications

Clinical Evidence and Recommendations

• The American College of Cardiology and other guideline societies recommend avoiding diphenhydramine in patients taking tamoxifen when possible, as CYP2D6 inhibition can reduce conversion to the active metabolite endoxifen 4, 5, 6
• The National Comprehensive Cancer Network recommends avoiding potent and intermediate CYP2D6 inhibitors, including diphenhydramine, in tamoxifen-treated patients 5
• Exercise caution when combining diphenhydramine with narrow therapeutic index CYP2D6 substrates, including tricyclic antidepressants, antipsychotics, flecainide, propafenone, and other beta-blockers beyond metoprolol 7
• Consider second-generation antihistamines, such as loratadine, cetirizine, or fexofenadine, when antihistamine therapy is needed in patients taking CYP2D6 substrates with narrow therapeutic indices 4, 6

Pharmacokinetics and Pharmacodynamics

• Diphenhydramine's inhibitory concentrations (2-11 μM) fall within the range of expected hepatic blood concentrations at therapeutic doses, making clinically relevant interactions probable, although the specific strength of evidence is not provided 8